LGM
EWTX icon

Logos Global Management’s Edgewise Therapeutics EWTX Stock Holding History

Logos Global Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-400,000
Closed -$10.7M – 47
2024
Q4 		$10.7M Sell
400,000
-50,000
-11% -$1.59M 1.25% 28
2024
Q3 		$12M Buy
+450,000
New +$8.95M 1.3% 27
2024
Q1 		– Sell
-950,000
Closed -$10.4M – 61
2023
Q4 		$10.4M Buy
+950,000
New +$6.67M 0.97% 23
2022
Q3 		– Sell
-150,000
Closed -$1.19M – 42
2022
Q2 		$1.19M Sell
150,000
-63,744
-30% -$482K 0.22% 25
2022
Q1 		$2.07M Sell
213,744
-636,256
-75% -$8.19M 0.27% 33
2021
Q4 		$13M Buy
850,000
+168,188
+25% +$3.03M 1.34% 22
2021
Q3 		$10.8M Sell
681,812
-550,000
-45% -$9.95M 0.78% 31
2021
Q2 		$26.3M Buy
1,231,812
+175,000
+17% +$4.78M 2.21% 18
2021
Q1 		$34.3M Buy
+1,056,812
New +$34.3M 3.35% 8

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Logos Global Management's EWTX Position: Q1 2025 in Review

Logos Global Management sold out of Edgewise Therapeutics (EWTX) in Q1 2025, closing a stake of 400,000 shares — an estimated $10.7M sold.

Logos Global Management first reported a position in EWTX in Q1 2021 and held it in 9 quarters. The position peaked at $34.3M in Q1 2021. 192 funds tracked by Wall St. Rank hold EWTX as of Q1 2025.

  • Logos Global Management reported no remaining Edgewise Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Logos Global Management sold 400,000 Edgewise Therapeutics shares in Q1 2025, an estimated $10.7M.
  • Logos Global Management first reported a position in Edgewise Therapeutics in Q1 2021 and held it in 9 quarters.
  • Logos Global Management's Edgewise Therapeutics position peaked at $34.3M in Q1 2021.
  • 192 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2025.

Based on Logos Global Management's 13F filing for Q1 2025, filed 15 May 2025.